Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Dr. Reddy's Laboratories Limited is a drug manufacturers-specialty & generic business based in the US. DrReddys Laboratories shares (RDY) are listed on the NYSE and all prices are listed in US Dollars. DrReddys Laboratories employs 21,650 staff and has a market cap (total outstanding shares value) of USD$10.2 billion.
|52-week range||USD$33.1177 - USD$73.39|
|50-day moving average||USD$67.1103|
|200-day moving average||USD$65.9336|
|Wall St. target price||USD$72.5|
|Dividend yield||USD$0.292 (0.48%)|
|Earnings per share (TTM)||USD$1.404|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing DrReddys Laboratories stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of DrReddys Laboratories's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
DrReddys Laboratories's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 44x. In other words, DrReddys Laboratories shares trade at around 44x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
DrReddys Laboratories's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.4157. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into DrReddys Laboratories's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
|Gross profit TTM||USD$94 billion|
|Return on assets TTM||8.56%|
|Return on equity TTM||13.37%|
|Market capitalisation||USD$10.2 billion|
TTM: trailing 12 months
There are currently 1.1 million DrReddys Laboratories shares held short by investors – that's known as DrReddys Laboratories's "short interest". This figure is 28.7% up from 845,264 last month.
There are a few different ways that this level of interest in shorting DrReddys Laboratories shares can be evaluated.
DrReddys Laboratories's "short interest ratio" (SIR) is the quantity of DrReddys Laboratories shares currently shorted divided by the average quantity of DrReddys Laboratories shares traded daily (recently around 165033.08042489). DrReddys Laboratories's SIR currently stands at 6.59. In other words for every 100,000 DrReddys Laboratories shares traded daily on the market, roughly 6590 shares are currently held short.
However DrReddys Laboratories's short interest can also be evaluated against the total number of DrReddys Laboratories shares, or, against the total number of tradable DrReddys Laboratories shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case DrReddys Laboratories's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 DrReddys Laboratories shares in existence, roughly 10 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable DrReddys Laboratories shares, roughly 0 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against DrReddys Laboratories.
Find out more about how you can short DrReddys Laboratories stock.
Dividend payout ratio: 19.2% of net profits
Recently DrReddys Laboratories has paid out, on average, around 19.2% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.53% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), DrReddys Laboratories shareholders could enjoy a 0.53% return on their shares, in the form of dividend payments. In DrReddys Laboratories's case, that would currently equate to about $0.292 per share.
While DrReddys Laboratories's payout ratio might seem low, this can signify that DrReddys Laboratories is investing more in its future growth.
DrReddys Laboratories's most recent dividend payout was on 17 August 2020. The latest dividend was paid out to all shareholders who bought their shares by 10 July 2020 (the "ex-dividend date").
DrReddys Laboratories's shares were split on a 2:1 basis on 7 September 2006. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your DrReddys Laboratories shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for DrReddys Laboratories shares which in turn could have impacted DrReddys Laboratories's share price.
Over the last 12 months, DrReddys Laboratories's shares have ranged in value from as little as $33.1177 up to $73.39. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while DrReddys Laboratories's is -0.0252. This would suggest that DrReddys Laboratories's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, DrReddys Laboratories has bucked the trend.
Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. It also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Proprietary Products segment focuses on the research, development, and manufacture of differentiated formulations for dermatology and neurology therapeutic areas. The company also engages in developing therapies in the fields of oncology and inflammation. As of March 31, 2020, it had four late stage projects at various stages of development. The company's therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. It has collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists; and partnership with Department of Biotechnology - Biotechnology Industry Research Assistance Council for Sputnik V vaccine clinical trials in India. The company was founded in 1984 and is headquartered in Hyderabad, India.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.